National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 59393 [2019-23997]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 213 / Monday, November 4, 2019 / Notices
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR–18–423:
NIDDK Multi-Center Clinical Study
Implementation Planning Cooperative
Agreements (U34).
Date: November 18, 2019.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Ann A. Jerkins, Ph.D.,
Scientific Review Officer, Review Branch,
Division of Extramural Activities, National
Institutes of Health, Room 7119, 6707
Democracy Boulevard, Bethesda, MD 20892–
5452, (301) 594–2242, jerkinsa@
niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: October 29, 2019.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–23996 Filed 11–1–19; 8:45 am]
BILLING CODE 4140–01–P
Contact Person: Lindsay M. Garvin, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Suite
7189, Bethesda, MD 20892, 301–827–7911,
lindsay.garvin@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: October 29, 2019.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–23997 Filed 11–1–19; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License for: Autologous Cell
Graft of Manufactured Retinal Pigment
Epithelium Cell(s) on a Biodegradable
Support Scaffold Transplanted SubRetinally for Intra-Ocular Ophthalmic
Treatment of Age-Related Macular
Degeneration in Humans
AGENCY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health,
HHS.
ACTION:
National Institutes of Health
Notice.
The National Eye Institute, an
institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the Supplementary Information
section of this notice to CellRay, LLC,
(‘‘CellRay’’) located in New York, New
York and its affiliates.
DATES: Only written comments and/or
complete applications for a license
which are received by the National
Cancer Institute’s Technology Transfer
Center on or before November 19, 2019
will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Edward Fenn., Senior
Technology Transfer Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702; Telephone: (240)-276–5530;
Facsimile: (240)-276–5504 Email:
Tedd.Fenn@nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Heart, Lung, and
Blood Initial Review Group; NHLBI
Institutional Training Mechanism Review
Committee.
Date: December 13, 2019.
Time: 9:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
VerDate Sep<11>2014
20:48 Nov 01, 2019
Jkt 250001
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
59393
Intellectual Property
• PCT Patent App. No. PCT/US2015/
039932, filed 07/10/15 (NIH Ref. E–192–
2014–1–PCT–01); United States Patent
App. No. 15/325,584, filed 01/11/17
(NIH Ref. E–192–2014–1–US–02);
Australia Patent App. No. 2015287692,
filed 07/10/15 (NIH Ref. E–192–2014–1–
AU–03); Canada Patent App. No.
2954762, filed 07/10/15 (NIH Ref. E–
192–2014–1–CA–04); PEC Patent App.
No. 15741462.4, filed 07/10/15 (NIH
Ref. E–192–2014–1–EP–05); India Patent
App. No. 21717003244, filed 01/30/17
(NIH Ref. E–192–2014–1–IN–06); Japan
Patent App. No. 2017–501212 Filed 01/
10/17 (NIH Ref. E–192–2014–1–JP–07);
each entitled ‘‘Surgical Tool and
Method for Ocular Tissue
Transplantation’’
• United States Patent App. No. 62/
215,579, filed 09/08/15 (NIH Ref. E–
212–2015–0–US–01); PCT Patent App.
No. PCT/US2016/050543, filed 09/07/16
(NIH Ref. E–212–2015–0–PCT–02);
United States Patent App. No. 15/
758,314, filed 03/07/18 (NIH Ref. E–
212–2015–0–US–07); each entitled
‘‘Method for Reproducible
Differentiation of Clinical-Grade Retinal
Pigment Epithelium Cells’’
• United States Provisional Patent
App. No. 62/419,804, filed 11/09/16
(NIH Ref. E–293–2016–0–US–01); PCT
Patent App. No. PCT/US2017/060672,
filed 11/08/17 (NIH Ref. E–293–2016–0–
PCT–02); Australia Patent App. No.
2017359336, filed 11/08/17 (NIH Ref. E–
293–2016–0–AU–04); Canada Patent
App. No. 3043174, filed 11/08/17 (NIH
Ref. E–293–2016–0–CA–05); EPC Patent
App. No. 17801272.0, filed 11/08/17
(NIH Ref. E–293–2016–0–EP–06); Japan
Patent App. No. 2017–545900 (NIH Ref.
E–293–2016–0–JP–07); United States
Patent App. No. 16/348,855, filed 05/09/
2019 (NIH Ref. E–293–2016–0–US–03);
each entitled ‘‘A Surgical Clamp to Gate
Large Scleral Surgery Port and Suture
Alignment Tool’’;
• United States Patent App. No. 62/
453,148, filed 02/01/17 (NIH Ref. E–
094–2016–0–US–01); PCT Patent App.
No. PCT/US2018/016101, Filed 01/31/
18 (NIH Ref. E–094–2016–0–PCT–02)
entitled ‘‘Devices for Tissue
Cryopreservation and Recovery’’ and;
United States Patent App. No. 16/
478,093 (NIH Ref. E–094–2016–0–US–
03); Australia Patent App. No.
2018214954 filed 01/31/18 (NIH Ref. E–
094–2016–0–AU–04); Canada Patent
App. No. 3048523 (NIH Ref. E–094–
2016–0–CA–05); EPC Patent App. No.
18704773.3 (NIH Ref. E–094–2016–0–
EP–06); Japan Patent App. No. 2019–
538157 (NIH Ref. E–094–2016–0–JP–07);
each ‘‘A Self-contained
E:\FR\FM\04NON1.SGM
04NON1
]]>Agencies
[Federal Register Volume 84, Number 213 (Monday, November 4, 2019)]
[Notices]
[Page 59393]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-23997]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Heart, Lung, and Blood Initial Review Group;
NHLBI Institutional Training Mechanism Review Committee.
Date: December 13, 2019.
Time: 9:30 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Lindsay M. Garvin, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Suite 7189, Bethesda, MD
20892, 301-827-7911, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: October 29, 2019.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-23997 Filed 11-1-19; 8:45 am]
BILLING CODE 4140-01-P
